Which has higher valuation and earnings, SHC or AZTA?

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.80 $77.94M $0.57 34.33 Azenta $613.81M 2.67 -$55.76M -$2.76 N/A

Is SHC or AZTA more profitable?

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 13.44% 40.12% 7.55% Azenta -20.63% 1.18% 0.97%

Does the media favor SHC or AZTA?

In the previous week, Sotera Health had 6 more articles in the media than Azenta. MarketBeat recorded 7 mentions for Sotera Health and 1 mentions for Azenta. Sotera Health's average media sentiment score of 0.15 beat Azenta's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Azenta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AZTA or ADPT?

In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Azenta. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 1 mentions for Azenta. Adaptive Biotechnologies' average media sentiment score of 0.70 beat Azenta's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALMR or AZTA?

In the previous week, Alamar Biosciences had 2 more articles in the media than Azenta. MarketBeat recorded 3 mentions for Alamar Biosciences and 1 mentions for Azenta. Alamar Biosciences' average media sentiment score of 0.89 beat Azenta's score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AZTA or FTRE?

Azenta has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Azenta $613.81M 2.67 -$55.76M -$2.76 N/A Fortrea $2.72B 0.64 -$986.20M -$0.91 N/A

Is AZTA or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Azenta -20.63% 1.18% 0.97% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to AZTA or FTRE?

In the previous week, Azenta and Azenta both had 1 articles in the media. Fortrea's average media sentiment score of 0.89 beat Azenta's score of 0.00 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLFS or AZTA?

In the previous week, BioLife Solutions had 5 more articles in the media than Azenta. MarketBeat recorded 6 mentions for BioLife Solutions and 1 mentions for Azenta. BioLife Solutions' average media sentiment score of 1.62 beat Azenta's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Azenta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Azenta (AZTA) Competitors

$37.40 +0.89 (+2.44%)

As of 08/21/2026 04:00 PM Eastern

Compare

AZTA vs. SHC, ADPT, ALMR, FTRE, and BLFS

Should you buy Azenta stock or one of its competitors? Azenta's main competitors and comparable companies include Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), Fortrea (FTRE), and BioLife Solutions (BLFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Azenta compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Sotera Health had 6 more articles in the media than Azenta. MarketBeat recorded 7 mentions for Sotera Health and 1 mentions for Azenta. Sotera Health's average media sentiment score of 0.15 beat Azenta's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Azenta	-20.63%	1.18%	0.97%

Sotera Health presently has a consensus target price of $21.50, indicating a potential upside of 9.86%. Azenta has a consensus target price of $41.20, indicating a potential upside of 10.16%. Given Azenta's higher probable upside, analysts clearly believe Azenta is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by insiders. Comparatively, 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.80	$77.94M	$0.57	34.33
Azenta	$613.81M	2.67	-$55.76M	-$2.76	N/A

Sotera Health has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Azenta has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Summary

Sotera Health beats Azenta on 14 of the 16 factors compared between the two stocks.

How does Azenta compare to Adaptive Biotechnologies?

Azenta (NASDAQ:AZTA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Azenta has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Azenta. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 1 mentions for Azenta. Adaptive Biotechnologies' average media sentiment score of 0.70 beat Azenta's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Azenta has a net margin of -20.63% compared to Adaptive Biotechnologies' net margin of -20.73%. Azenta's return on equity of 1.18% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Azenta has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$613.81M	2.67	-$55.76M	-$2.76	N/A
Adaptive Biotechnologies	$276.98M	14.98	-$59.50M	-$0.41	N/A

Azenta currently has a consensus target price of $41.20, suggesting a potential upside of 10.16%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 6.05%. Given Azenta's higher probable upside, research analysts clearly believe Azenta is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

99.1% of Azenta shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Azenta and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Azenta compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Alamar Biosciences has a net margin of 0.00% compared to Azenta's net margin of -20.63%. Azenta's return on equity of 1.18% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Azenta	-20.63%	1.18%	0.97%

99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alamar Biosciences currently has a consensus target price of $31.80, indicating a potential downside of 7.13%. Azenta has a consensus target price of $41.20, indicating a potential upside of 10.16%. Given Azenta's higher probable upside, analysts clearly believe Azenta is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has higher earnings, but lower revenue than Azenta. Alamar Biosciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	32.02	-$29.82M	-$1.96	N/A
Azenta	$613.81M	2.67	-$55.76M	-$2.76	N/A

In the previous week, Alamar Biosciences had 2 more articles in the media than Azenta. MarketBeat recorded 3 mentions for Alamar Biosciences and 1 mentions for Azenta. Alamar Biosciences' average media sentiment score of 0.89 beat Azenta's score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Azenta beats Alamar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Azenta compare to Fortrea?

Azenta (NASDAQ:AZTA) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Azenta has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Fortrea	-3.18%	10.72%	2.17%

Azenta currently has a consensus price target of $41.20, suggesting a potential upside of 10.16%. Fortrea has a consensus price target of $20.75, suggesting a potential upside of 12.83%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Azenta has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$613.81M	2.67	-$55.76M	-$2.76	N/A
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A

99.1% of Azenta shares are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Azenta and Azenta both had 1 articles in the media. Fortrea's average media sentiment score of 0.89 beat Azenta's score of 0.00 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fortrea beats Azenta on 9 of the 15 factors compared between the two stocks.

How does Azenta compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioLife Solutions has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Azenta has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

BioLife Solutions presently has a consensus price target of $31.38, indicating a potential downside of 15.43%. Azenta has a consensus price target of $41.20, indicating a potential upside of 10.16%. Given Azenta's stronger consensus rating and higher possible upside, analysts clearly believe Azenta is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, BioLife Solutions had 5 more articles in the media than Azenta. MarketBeat recorded 6 mentions for BioLife Solutions and 1 mentions for Azenta. BioLife Solutions' average media sentiment score of 1.62 beat Azenta's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLife Solutions has a net margin of 53.29% compared to Azenta's net margin of -20.63%. BioLife Solutions' return on equity of 2.70% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Azenta	-20.63%	1.18%	0.97%

BioLife Solutions has higher earnings, but lower revenue than Azenta. Azenta is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$106.69M	16.99	-$4.59M	$1.16	31.98
Azenta	$613.81M	2.67	-$55.76M	-$2.76	N/A

Summary

BioLife Solutions beats Azenta on 11 of the 17 factors compared between the two stocks.

Get Azenta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZTA vs. The Competition

Export

Metric	Azenta	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60B	$10.01B	$7.27B	$12.76B
Dividend Yield	N/A	1.46%	2.54%	11.08%
P/E Ratio	-13.55	61.54	270.69	24.20
Price / Sales	2.67	110.53	639.59	109.19
Price / Cash	20.14	27.21	76.89	53.23
Price / Book	1.09	37.34	13.43	6.37
Net Income	-$55.76M	$56.67B	$3.46B	$347.74M
7 Day Performance	12.04%	5.22%	2.15%	0.08%
1 Month Performance	37.70%	9.81%	6.17%	2.90%
1 Year Performance	18.54%	24.61%	24.96%	17.22%

Azenta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZTA Azenta	1.3701 of 5 stars	$37.40 +2.4%	$41.20 +10.2%	+25.3%	$1.60B	$613.81M	N/A	3,000
SHC Sotera Health	3.5816 of 5 stars	$18.97 +0.6%	$21.50 +13.3%	+22.8%	$5.38B	$1.16B	33.28	3,000	Insider Trade
ADPT Adaptive Biotechnologies	1.5151 of 5 stars	$25.45 +2.1%	$24.42 -4.1%	+105.8%	$3.98B	$276.98M	N/A	790	Insider Trade
ALMR Alamar Biosciences	1.202 of 5 stars	$27.99 -1.7%	$30.00 +7.2%	N/A	$1.97B	$74.21M	N/A	222	Gap Up
FTRE Fortrea	3.353 of 5 stars	$18.99 +3.0%	$20.75 +9.3%	+137.6%	$1.75B	$2.72B	N/A	14,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AZTA) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, FTRE, and BLFS

How does Azenta compare to Sotera Health?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Summary

How does Azenta compare to Alamar Biosciences?

Summary

How does Azenta compare to Fortrea?

Summary

How does Azenta compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, FTRE, and BLFS

How does Azenta compare to Sotera Health?

Does the media favor SHC or AZTA?

Is SHC or AZTA more profitable?

Do analysts rate SHC or AZTA?

Do insiders & institutionals have more ownership in SHC or AZTA?

Which has higher valuation and earnings, SHC or AZTA?

Which has more risk & volatility, SHC or AZTA?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Which has more risk & volatility, AZTA or ADPT?

Does the media refer more to AZTA or ADPT?

Is AZTA or ADPT more profitable?

Which has better earnings & valuation, AZTA or ADPT?

Do analysts prefer AZTA or ADPT?

Do institutionals & insiders hold more shares of AZTA or ADPT?

Summary

How does Azenta compare to Alamar Biosciences?

Is ALMR or AZTA more profitable?

Do institutionals and insiders believe in ALMR or AZTA?

Do analysts prefer ALMR or AZTA?

Which has preferable earnings & valuation, ALMR or AZTA?

Does the media favor ALMR or AZTA?

Summary

How does Azenta compare to Fortrea?

Which has more risk & volatility, AZTA or FTRE?

Is AZTA or FTRE more profitable?

Do analysts prefer AZTA or FTRE?

Which has higher earnings & valuation, AZTA or FTRE?

Do institutionals & insiders hold more shares of AZTA or FTRE?

Does the media refer more to AZTA or FTRE?

Summary

How does Azenta compare to BioLife Solutions?

Do insiders and institutionals believe in BLFS or AZTA?

Which has more volatility & risk, BLFS or AZTA?

Do analysts recommend BLFS or AZTA?

Does the media prefer BLFS or AZTA?

Is BLFS or AZTA more profitable?

Which has better valuation & earnings, BLFS or AZTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools